A Phase 2 interventional study of Zilucoplan (RA101495) in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Ra Pharmaceuticals, Inc.. Terminated at 12 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-28.
Sponsored by Ra Pharmaceuticals, Inc. (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Hemoglobinuria, Paroxysmal with a site in United States — 10 open to participants now, 16 under way, 4 of them phase 3. Hemoglobinuria, Paroxysmal · United States.
Among the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States, this one is the 39th largest by enrollment of the 54 interventional ones that give a count, is one of 6 that started in 2017, is one of 21 in phase 2, and was the 39th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →10 of the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Brazil, Colombia and 3 more countries
Ages 2–18
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, France and 4 more countries
Women only
Novartis Pharmaceuticals · Sites in United States
Ages 18–99
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages 0–75
International PNH Interest Group · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 53 across the 54 interventional studies, 75 across the 13 observational. Of the 50 that completed or were terminated, 26 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 68 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ra Pharmaceuticals, Inc., one of the names counted as UCB S.A.. Under that name alone:
Ra Pharmaceuticals, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
UCB S.A. has 3 studies filed under Hemoglobinuria, Paroxysmal — fewer than ten, so there is no comparison to draw.
3 of the studies in Hemoglobinuria, Paroxysmal with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04432584Phase 3Hoffmann-La RocheA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors | 2027-04-18 |
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
| NCT03520647National Heart, Lung, and Blood Institute (NHLBI)Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to enable continued access to zilucoplan (RA101495) for patients with paroxysmal nocturnal hemoglobinuria (PNH) after they complete a zilucoplan clinical study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study
Drug: Zilucoplan (RA101495)
Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study.
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
TEAEs were defined as an AE that occurs after a participant's initial treatment zilucoplan start for this study (RA101495-01.202) that was not present at the time of treatment start, or an AE that increases in severity after treatment start in this study, if the event was present at the time of treatment start.
Time frame: From Day 1 until the Final Study Visit (up to Month 49)
Percentage of Participants With Serious TEAEs
Serious Adverse event (SAE) was defined as any untoward medical occurrence that:• results in death, • is life-threatening threatening (note that this refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe), • requires hospitalization or prolongation of existing hospitalization, • results in persistent or significant disability/incapacity, and • results in a congenital anomaly/birth defect.
Time frame: From Day 1 until the Final Study Visit (up to Month 49)
Number of Participants With Anti-drug Antibodies (ADA)
Blood samples collection were planned to analyze for the presence/absence of ADAs to zilucoplan for immunogenicity assessments.
Time frame: At Day 1, Month 1, 2, 3, 6, 9, and 12
Change From Baseline in Serum Lactate Dehydrogenase (LDH) Levels at Each Time Point
Serum LDH levels were measure of intravascular hemolysis. As high level of LDH in the blood was indicative of hemolysis in participants with PNH.
Time frame: Baseline, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and Final Study Visit (Month 49)
Change From Baseline in Total Bilirubin Values at Each Time Point
Total Bilirubin was monitored for signs and symptoms of hepatic or biliary dysfunction.
Time frame: Baseline, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and Final Study Visit (Month 49)
Change From Baseline in Total Hemoglobin Values at Each Time Point
Total Hemoglobin Values were analyzed for hematology assessments.
Time frame: Baseline, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and Final Study Visit (Month 49)
Change From Baseline in Free Hemoglobin Values at Each Time Point
Free Hemoglobin Values were analyzed for hematology assessments.
Time frame: Baseline, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and Final Study Visit (Month 49)
Change From Baseline in Haptoglobin Values at Each Time Point
Haptoglobin values were analyzed for hematology assessments.
Time frame: Baseline, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and Final Study Visit (Month 49)
Change From Baseline in Reticulocytes at Each Time Point
Reticulocytes values were analyzed for hematology assessments.
Time frame: Baseline, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and Final Study Visit (Month 49)
Change From Baseline in Hemoglobinuria Values at Each Time Point
Hemoglobinuria was assessed using a urine colorimetric scoring system with a score of 1 through 10 where 1 represents no hemoglobinuria and 10 represents maximum hemoglobinuria.
Time frame: Baseline, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48 and Final Study Visit (Month 49)
Plasma Concentrations of RA101495 and Its Major Metabolite(s)
Blood samples of RA101495 (zilucoplan) and its metabolites (RA102758 and RA103488) were collected for Plasma concentration analysis.
Time frame: Predose: At Day 1 (Screening), Month 1, 2, 3, 6, 9, 12, and Final Study Visit (Month 49)
Maximum Plasma Concentration (Cmax) of RA101495
Cmax is the maximum plasma concentration.
Time frame: At Day 1, Month 1, 2, 3, 6, 9, and 12
Time Corresponding to Cmax (Tmax) of RA101495
tmax is the time to corresponding Cmax.
Time frame: At Day 1, Month 1, 2, 3, 6, 9, and 12
Area Under the Drug Concentration-time Curve (AUC0-t) of RA101495
AUC0-t is area under the drug concentration-time curves.
Time frame: At Day 1, Month 1, 2, 3, 6, 9, and 12
Total Complement (CH50) Levels
Blood samples collection were planned to assess complement (CH50) levels. The planned analysis of CH50 was not performed because the CH50 assay was not able to be validated due to lack of reproducibility of the manufacturer's kits.
Time frame: At Day 1, Month 1, 2, 3, 6, 9, and 12
Change From Baseline in Sheep Red Blood Cell (sRBC) Values at Each Time Point
Blood samples were collected for measurement of sRBC lysis for the Classical Complement Pathways.
Time frame: Baseline, Month 1, 2, 3, 6, 9, 12 and Final Study Visit (Month 49)
Change From Baseline in Wieslab Enzyme-linked Immunosorbent Assay (ELISA) Values for Alternative Complement Pathway at Each Time Point
Blood samples were collected for measurement of membrane attack complex (MAC) by Wieslab ELISA for alternative complement pathway.
Time frame: Baseline, Month 1, 2, 3, 6, 9, 12 and Final Study Visit (Month 49)
Change From Baseline in Complement Component 5 (C5) Values at Each Time Point
Blood samples were collected for measurement of Complement component 5 (C5) levels.
Time frame: Baseline, Month 1, 2, 3, 6, 9, 12 and Final Study Visit (Month 49)
The study started to enroll participants in July 2017 and concluded in October 2021.
| Milestone | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) |
|---|---|---|---|
| Started | 10 | 6 | 3 |
| Completed | 0 | 0 | 0 |
| Not completed | 10 | 6 | 3 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Protocol non-compliance | 0 | 0 | 1 |
| Withdrew: Subject withdraws consent | 3 | 0 | 0 |
| Withdrew: Sponsor, regulatory, or ec/irb request | 7 | 3 | 1 |
| Withdrew: Trial drug not effective | 0 | 1 | 0 |
| Withdrew: Need of transfusions and signs of hemolysis | 0 | 1 | 0 |
| Withdrew: Stem cell transplantation | 0 | 1 | 0 |
TEAEs were defined as an AE that occurs after a participant's initial treatment zilucoplan start for this study (RA101495-01.202) that was not present at the time of treatment start, or an AE that increases in severity after treatment start in this study, if the event was present at the time of treatment start.
| percentage of participants | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) |
|---|---|---|---|
| Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) | 90.0 | 100 | 66.7 |
Serious Adverse event (SAE) was defined as any untoward medical occurrence that:• results in death, • is life-threatening threatening (note that this refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe), • requires hospitalization or prolongation of existing hospitalization, • results in persistent or significant disability/incapacity, and • results in a congenital anomaly/birth defect.
| percentage of participants | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) |
|---|---|---|---|
| Percentage of Participants With Serious TEAEs | 10.0 | 50.0 | 66.7 |
Blood samples collection were planned to analyze for the presence/absence of ADAs to zilucoplan for immunogenicity assessments.
No measurements were reported for this outcome.
Serum LDH levels were measure of intravascular hemolysis. As high level of LDH in the blood was indicative of hemolysis in participants with PNH.
| Units per litre (U/L) | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) |
|---|---|---|---|
| Month 1 | -3.7 ± 71.5 | 10.0 ± 16.4 | 336.7 ± 636.9 |
| Month 2 | 50.3 ± 156.2 | -2.4 ± 22.2 | 676.5 ± 970.9 |
| Month 3 | -6.5 ± 58.2 | -1.6 ± 40.5 | 39.5 ± 40.3 |
| Month 6 | 32.4 ± 142.5 | -28.4 ± 127.3 | -3.5 ± 12.0 |
| Month 9 | -18.1 ± 59.7 | 22.7 ± 23.6 | -5.0 ± 35.4 |
| Month 12 | -39.7 ± 54.9 | 8.7 ± 10.1 | 456.0 ± 640.6 |
| Month 15 | -24.5 ± 70.8 | 4.0 ± 30.4 | 174.5 ± 215.7 |
| Month 18 | -27.9 ± 54.8 | 5.7 ± 56.8 | -56.0 ± NA |
| Month 21 | -12.0 ± 93.9 | -7.3 ± 33.5 | 73.0 ± NA |
| Month 24 | -18.7 ± 53.9 | -27.0 ± 64.1 | -29.0 ± NA |
| Month 27 | -14.0 ± 99.3 | 58.0 ± 8.5 | — |
| Month 30 | -28.0 ± 36.1 | 59.0 ± 140.0 | 1817.0 ± NA |
| Month 33 | -39.0 ± 65.9 | -16.3 ± 66.7 | — |
| Month 36 | -61.6 ± 47.1 | 0.5 ± 4.9 | — |
| Month 39 | -78.4 ± 80.9 | -29.7 ± 83.5 | — |
| Month 42 | -42.3 ± 78.3 | 35.5 ± 75.7 | — |
| Month 45 | 27.0 ± NA | 53.0 ± NA | — |
| Final Study Visit (Month 49) | 41.6 ± 303.1 | -93.2 ± 139.8 | 682.0 ± 548.7 |
Total Bilirubin was monitored for signs and symptoms of hepatic or biliary dysfunction.
| micromole per litre (umol/L) | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) |
|---|---|---|---|
| Month 1 | -2.1 ± 7.7 | 1.7 ± 6.2 | -0.3 ± 4.5 |
| Month 2 | 0.1 ± 10.7 | 2.0 ± 7.2 | 6.0 ± 2.8 |
| Month 3 | 1.4 ± 13.7 | 8.2 ± 13.1 | 3.5 ± 2.1 |
| Month 6 | 4.6 ± 14.8 | 3.2 ± 7.2 | 2.5 ± 0.7 |
| Month 9 | -0.3 ± 7.4 | 6.0 ± 3.0 | -1.0 ± 1.4 |
| Month 12 | 3.9 ± 8.4 | 3.0 ± 2.0 | 2.5 ± 3.5 |
| Month 15 | -0.4 ± 6.4 | 6.0 ± 9.5 | 8.5 ± 9.2 |
| Month 18 | 2.8 ± 9.5 | 2.0 ± 6.2 | 3.0 ± NA |
| Month 21 | 3.9 ± 8.3 | 2.0 ± 7.8 | 7.0 ± NA |
| Month 24 | 5.1 ± 16.0 | -1.3 ± 3.1 | 8.0 ± NA |
| Month 27 | 4.3 ± 12.2 | -2.0 ± 5.7 | — |
| Month 30 | 5.8 ± 14.6 | 3.0 ± 7.1 | 13.0 ± NA |
| Month 33 | 2.6 ± 5.7 | 3.0 ± 2.6 | — |
| Month 36 | -3.8 ± 6.8 | 3.0 ± 0.0 | — |
| Month 39 | 0.2 ± 3.1 | 0.7 ± 4.6 | — |
| Month 42 | 4.8 ± 15.5 | 4.0 ± 15.6 | — |
| Month 45 | 5.0 ± 17.0 | -2.0 ± NA | — |
| Final Study Visit (Month 49) | 8.0 ± 17.3 | 0.4 ± 3.9 | 0.0 ± 9.9 |
Total Hemoglobin Values were analyzed for hematology assessments.
| grams per litre (g/L) | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) |
|---|---|---|---|
| Month 1 | 0.0 ± 11.4 | 0.0 ± 8.2 | -5.7 ± 3.8 |
| Month 2 | 1.1 ± 8.3 | -5.0 ± 9.9 | -2.0 ± 11.3 |
| Month 3 | 6.4 ± 6.4 | 3.0 ± 9.1 | -3.5 ± 6.4 |
| Month 6 | 1.1 ± 11.2 | 2.0 ± 17.9 | -5.0 ± 17.0 |
| Month 9 | 2.9 ± 7.1 | -1.3 ± 4.0 | -9.0 ± 5.7 |
| Month 12 | 2.9 ± 6.1 | -1.7 ± 6.8 | -5.0 ± 17.0 |
| Month 15 | 3.9 ± 8.4 | -5.0 ± 5.3 | -9.0 ± 28.3 |
| Month 18 | 5.0 ± 4.9 | 1.7 ± 9.5 | -2.0 ± NA |
| Month 21 | 6.4 ± 6.3 | -6.7 ± 7.6 | -1.0 ± NA |
| Month 24 | 7.9 ± 12.6 | -5.0 ± 2.6 | — |
| Month 27 | 7.0 ± 10.0 | -5.0 ± 11.3 | — |
| Month 30 | 10.8 ± 7.0 | -4.5 ± 12.0 | -8.0 ± NA |
| Month 33 | 10.0 ± 8.8 | -3.0 ± 4.4 | — |
| Month 36 | 8.4 ± 14.2 | -2.0 ± 4.2 | — |
| Month 39 | 7.6 ± 10.1 | 4.7 ± 2.9 | — |
| Month 42 | 5.2 ± 11.2 | 5.5 ± 0.7 | — |
| Month 45 | -1.3 ± 23.3 | -4.0 ± NA | — |
| Final Study Visit (Month 49) | 1.8 ± 10.6 | -2.0 ± 4.1 | -7.0 ± NA |
Free Hemoglobin Values were analyzed for hematology assessments.
| milligrams per decilitre (mg/dL) | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) |
|---|---|---|---|
| Month 1 | -0.20 ± 2.78 | 2.86 ± 4.30 | 0.80 ± 4.38 |
| Month 2 | -1.14 ± 3.04 | 0.48 ± 1.77 | 6.10 ± NA |
| Month 3 | 1.34 ± 0.48 | -0.02 ± 0.95 | 0.80 ± NA |
| Month 6 | -0.43 ± 1.24 | 0.55 ± 2.45 | 1.20 ± NA |
| Month 9 | -1.10 ± 2.11 | -1.50 ± 1.57 | 0.00 ± NA |
| Month 12 | -0.56 ± 2.80 | 0.80 ± 0.28 | 2.10 ± NA |
| Month 15 | 3.93 ± 11.61 | -1.35 ± 2.19 | 1.60 ± NA |
| Month 18 | 1.98 ± 3.05 | 0.77 ± 1.56 | — |
| Month 21 | 3.15 ± 5.84 | -1.30 ± 0.85 | — |
| Month 24 | 0.27 ± 0.35 | -0.50 ± 0.99 | — |
| Month 30 | 0.33 ± 2.37 | — | — |
| Month 33 | 0.17 ± 2.66 | 5.80 ± NA | — |
| Month 39 | -0.60 ± NA | -0.95 ± 0.64 | — |
| Month 42 | 1.30 ± NA | 0.50 ± 3.68 | — |
| Final Study Visit (Month 49) | -2.70 ± NA | -0.60 ± 1.13 | -3.10 ± NA |
Haptoglobin values were analyzed for hematology assessments.
| g/L | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) |
|---|---|---|---|
| Month 1 | 0.032 ± 0.097 | 0.000 ± 0.000 | 0.000 ± 0.000 |
| Month 2 | 0.053 ± 0.160 | 0.000 ± 0.000 | 0.000 ± 0.000 |
| Month 3 | 0.021 ± 0.060 | 0.000 ± 0.000 | 0.000 ± 0.000 |
| Month 6 | 0.031 ± 0.088 | 0.036 ± 0.080 | 0.020 ± 0.028 |
| Month 9 | 0.008 ± 0.021 | 0.000 ± 0.000 | 0.000 ± 0.000 |
| Month 12 | 0.000 ± 0.000 | 0.000 ± 0.000 | 0.000 ± 0.000 |
| Month 15 | 0.000 ± 0.000 | 0.000 ± 0.000 | 0.000 ± 0.000 |
| Month 18 | 0.000 ± 0.000 | 0.000 ± 0.000 | 0.000 ± NA |
| Month 21 | 0.030 ± 0.079 | 0.000 ± 0.000 | 0.000 ± NA |
| Month 24 | 0.030 ± 0.079 | 0.000 ± 0.000 | 0.000 ± NA |
| Month 27 | 0.000 ± 0.000 | 0.000 ± 0.000 | — |
| Month 30 | 0.004 ± 0.009 | 0.000 ± 0.000 | 0.000 ± NA |
| Month 33 | 0.002 ± 0.004 | 0.000 ± 0.000 | — |
| Month 36 | 0.036 ± 0.080 | 0.000 ± 0.000 | — |
| Month 39 | 0.020 ± 0.045 | 0.000 ± 0.000 | — |
| Month 42 | 0.034 ± 0.076 | 0.000 ± 0.000 | — |
| Month 45 | 0.080 ± 0.113 | 0.000 ± NA | — |
| Final Study Visit (Month 49) | 0.042 ± 0.127 | 0.006 ± 0.013 | 0.000 ± 0.000 |
Reticulocytes values were analyzed for hematology assessments.
| 10^12 reticulocytes (cells)/L | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) |
|---|---|---|---|
| Month 1 | 0.0104 ± 0.0484 | 0.0107 ± 0.0299 | -0.0457 ± 0.0505 |
| Month 2 | -0.0046 ± 0.0354 | -0.0046 ± 0.0130 | 0.0115 ± 0.0049 |
| Month 3 | -0.0249 ± 0.0310 | -0.0112 ± 0.0251 | 0.0170 ± 0.0113 |
| Month 6 | -0.0006 ± 0.0452 | -0.0042 ± 0.0363 | 0.0200 ± 0.0382 |
| Month 9 | 0.0063 ± 0.0334 | 0.0070 ± 0.0171 | 0.0640 ± 0.0297 |
| Month 12 | -0.0041 ± 0.0427 | -0.0070 ± 0.0346 | 0.0240 ± 0.0113 |
| Month 15 | -0.0264 ± 0.0601 | -0.0343 ± 0.0191 | 0.0285 ± 0.0290 |
| Month 18 | -0.0040 ± 0.0382 | 0.0027 ± 0.0380 | 0.0460 ± NA |
| Month 21 | -0.0223 ± 0.0554 | -0.0087 ± 0.0380 | — |
| Month 24 | -0.0123 ± 0.0711 | -0.0093 ± 0.0186 | — |
| Month 27 | -0.0017 ± 0.0553 | 0.0150 ± 0.0127 | — |
| Month 30 | 0.0016 ± 0.0524 | 0.0060 ± 0.0594 | 0.0300 ± NA |
| Month 33 | -0.0302 ± 0.0446 | -0.0093 ± 0.0234 | — |
| Month 36 | -0.0630 ± 0.0621 | -0.0215 ± 0.0078 | — |
| Month 39 | -0.0340 ± 0.0860 | -0.0133 ± 0.0291 | — |
| Month 42 | -0.0270 ± 0.0721 | -0.0015 ± 0.0078 | — |
| Month 45 | -0.0423 ± 0.1189 | -0.0050 ± NA | — |
| Final Study Visit (Month 49) | -0.0433 ± 0.0480 | -0.0333 ± 0.0116 | 0.0100 ± NA |
Hemoglobinuria was assessed using a urine colorimetric scoring system with a score of 1 through 10 where 1 represents no hemoglobinuria and 10 represents maximum hemoglobinuria.
| score on a scale | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) |
|---|---|---|---|
| Month 1 | 0.1 ± 1.0 | 0.2 ± 1.5 | 1.7 ± 1.5 |
| Month 2 | 0.9 ± 1.4 | 0.8 ± 1.3 | 1.0 ± 1.4 |
| Month 3 | 0.4 ± 1.2 | 0.8 ± 1.3 | 0.0 ± NA |
| Month 6 | 0.4 ± 0.9 | 0.8 ± 1.3 | 0.0 ± NA |
| Month 9 | 0.4 ± 0.9 | 1.5 ± 2.1 | 0.0 ± NA |
| Month 12 | 0.9 ± 1.4 | 1.0 ± 1.7 | 1.0 ± 1.4 |
| Month 15 | 0.9 ± 1.1 | 1.0 ± 1.7 | 1.0 ± 1.4 |
| Month 18 | 0.1 ± 0.9 | 0.3 ± 0.6 | 0.0 ± NA |
| Month 21 | 0.7 ± 1.6 | 1.0 ± 1.7 | 0.0 ± NA |
| Month 24 | 0.6 ± 1.6 | 0.3 ± 0.6 | 0.0 ± NA |
| Month 27 | 0.7 ± 1.5 | 1.5 ± 2.1 | 0.0 ± NA |
| Month 30 | 0.6 ± 1.3 | 1.5 ± 2.1 | 0.0 ± NA |
| Month 33 | 1.4 ± 0.9 | 1.0 ± 1.7 | — |
| Month 36 | 1.4 ± 1.9 | 1.5 ± 2.1 | — |
| Month 39 | 0.4 ± 1.7 | 1.0 ± 1.7 | — |
| Month 42 | 1.0 ± 1.2 | 1.5 ± 2.1 | — |
| Month 45 | 1.0 ± 1.0 | -1.0 ± NA | — |
| Final Study Visit (Month 49) | 0.4 ± 1.1 | 0.6 ± 0.9 | 2.5 ± 3.5 |
Blood samples of RA101495 (zilucoplan) and its metabolites (RA102758 and RA103488) were collected for Plasma concentration analysis.
| micrograms per litre (ug/L) | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) |
|---|---|---|---|
| RA101495- Day 1 | 10999.99 ± 2698.29 | 13616.08 ± 1490.81 | 6976.50 ± 5663.23 |
| RA101495- Month 1 | 10879.13 ± 2405.19 | 12645.38 ± 1620.31 | 7630.03 ± 7060.56 |
| RA101495- Month 2 | 11276.17 ± 2896.98 | 12220.10 ± 2188.78 | 6865.45 ± 8108.18 |
| RA101495- Month 3 | 10806.17 ± 3418.92 | 12315.28 ± 2515.84 | 12430.00 ± 16.55 |
| RA101495- Month 6 | 9393.42 ± 2224.52 | 12218.72 ± 2166.05 | 12254.00 ± NA |
| RA101495- Month 9 | 11848.67 ± 2685.92 | 12282.83 ± 3064.42 | 15193.35 ± 2756.66 |
| RA101495- Month 12 | 11495.99 ± 2885.81 | 13279.97 ± 2148.60 | 12038.65 ± 7934.94 |
| RA101495- Final Study Visit (Month 49) | — | — | 7174.20 ± NA |
| RA102758- Day 1 | 1883.49 ± 593.93 | 2443.62 ± 560.97 | 1280.07 ± 1109.03 |
| RA102758- Month 1 | 1865.06 ± 594.31 | 2185.00 ± 631.37 | 757.30 ± 997.44 |
| RA102758- Month 2 | 1894.86 ± 608.46 | 2090.04 ± 831.80 | 757.85 ± 1018.59 |
| RA102758- Month 3 | 1758.55 ± 689.03 | 1990.54 ± 700.70 | 1954.05 ± 160.58 |
| RA102758- Month 6 | 1467.85 ± 563.68 | 1819.20 ± 613.14 | 1725.50 ± NA |
| RA102758- Month 9 | 1686.80 ± 554.87 | 1881.73 ± 583.87 | 1238.55 ± 166.24 |
| RA102758- Month 12 | 1646.99 ± 536.00 | 1954.23 ± 725.54 | 10.00 ± NA |
| RA102758- Final Study Visit (Month 49) | — | — | 1094.60 ± NA |
| RA103488- Day 1 | 3587.68 ± 1747.12 | 4887.98 ± 1969.22 | 2084.83 ± 1791.35 |
| RA103488- Month 1 | 4344.99 ± 2319.10 | 4400.68 ± 1823.93 | 1703.73 ± 1605.96 |
| RA103488- Month 2 | 4799.29 ± 3113.57 | 4365.84 ± 1537.67 | 1591.35 ± 1552.03 |
| RA103488- Month 3 | 4191.36 ± 2347.65 | 4541.78 ± 1706.07 | 2715.60 ± 1345.48 |
| RA103488- Month 6 | 4027.53 ± 2730.92 | 4436.46 ± 2341.16 | 1929.60 ± NA |
| RA103488- Month 9 | 3132.54 ± 1320.61 | 4217.97 ± 2015.36 | 2954.85 ± 1754.97 |
| RA103488- Month 12 | 3903.41 ± 1960.30 | 4334.47 ± 1976.47 | 2319.20 ± 2534.84 |
| RA103488- Final Study Visit (Month 49) | — | — | 2210.00 ± NA |
Cmax is the maximum plasma concentration.
No measurements were reported for this outcome.
tmax is the time to corresponding Cmax.
No measurements were reported for this outcome.
AUC0-t is area under the drug concentration-time curves.
No measurements were reported for this outcome.
Blood samples collection were planned to assess complement (CH50) levels. The planned analysis of CH50 was not performed because the CH50 assay was not able to be validated due to lack of reproducibility of the manufacturer's kits.
No measurements were reported for this outcome.
Blood samples were collected for measurement of sRBC lysis for the Classical Complement Pathways.
| percent lysis of sheep erythrocytes | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) |
|---|---|---|---|
| Month 1 | 1.378 ± 2.277 | 0.523 ± 0.772 | 93.870 ± NA |
| Month 2 | 1.248 ± 1.789 | -0.308 ± 0.452 | 93.870 ± NA |
| Month 3 | 1.256 ± 1.799 | 0.576 ± 0.972 | -2.620 ± NA |
| Month 6 | 1.493 ± 2.838 | 0.458 ± 1.657 | -2.300 ± NA |
| Month 9 | 0.683 ± 1.055 | 0.757 ± 0.673 | -1.410 ± NA |
| Month 12 | 0.759 ± 0.557 | 0.773 ± 0.415 | 8.390 ± NA |
| Final Study Visit (Month 49) | — | 25.230 ± 35.200 | — |
Blood samples were collected for measurement of membrane attack complex (MAC) by Wieslab ELISA for alternative complement pathway.
| percentage of activity | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) |
|---|---|---|---|
| Month 1 | 1.7 ± 5.8 | 1.0 ± 1.7 | 48.0 ± 67.9 |
| Month 2 | 0.1 ± 1.9 | -1.0 ± 1.0 | 51.5 ± 74.2 |
| Month 3 | 0.1 ± 2.0 | 0.0 ± 0.7 | 2.0 ± 1.4 |
| Month 6 | 1.0 ± 4.5 | -0.2 ± 1.9 | 5.0 ± NA |
| Month 9 | -0.9 ± 0.8 | -0.7 ± 0.6 | -2.0 ± NA |
| Month 12 | -1.4 ± 1.4 | -1.3 ± 0.6 | 4.5 ± 6.4 |
| Final Study Visit (Month 49) | — | 1.0 ± 2.8 | — |
Blood samples were collected for measurement of Complement component 5 (C5) levels.
| ug/mL | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) |
|---|---|---|---|
| Month 1 | -11.231 ± 24.960 | 20.488 ± 31.024 | -27.505 ± 90.092 |
| Month 2 | -15.914 ± 32.737 | 17.716 ± 33.125 | 16.310 ± 36.077 |
| Month 3 | -24.404 ± 50.084 | -2.898 ± 49.747 | 22.355 ± 19.764 |
| Month 6 | -6.823 ± 44.787 | 9.572 ± 24.927 | 91.640 ± NA |
| Month 9 | -0.019 ± 53.475 | 1.177 ± 27.654 | 89.670 ± NA |
| Month 12 | -40.591 ± 34.977 | -23.487 ± 30.911 | -24.905 ± 17.685 |
| Final Study Visit (Month 49) | -28.663 ± 46.526 | -19.770 ± 74.604 | — |
Collected over From Day 1 until the Final Study Visit (up to Month 49). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zilucoplan-Cohort A (Eculizumab Naïve) | 0/10 (0%) | 1/10 (10%) | 9/10 (90%) |
| Zilucoplan-Cohort B (Eculizumab Switch) | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Zilucoplan (Inadequate Responder to Eculizumab) | 0/3 (0%) | 2/3 (66.7%) | 2/3 (66.7%) |
| Event | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/10 | 0/6 | 1/3 |
| Pneumonia pneumococcalInfections and infestations | 0/10 | 0/6 | 1/3 |
| EncephalopathyNervous system disorders | 0/10 | 0/6 | 1/3 |
| Suicide attemptPsychiatric disorders | 0/10 | 0/6 | 1/3 |
| Tongue haematomaGastrointestinal disorders | 0/10 | 1/6 | 0/3 |
| Enterocolitis infectiousInfections and infestations | 0/10 | 1/6 | 0/3 |
| Deep vein thrombosisVascular disorders | 0/10 | 1/6 | 0/3 |
| NauseaGastrointestinal disorders | 1/10 | 0/6 | 0/3 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/10 | 0/6 | 0/3 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 1/10 | 0/6 | 0/3 |
| Event | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/10 | 1/6 | 0/3 |
| NauseaGastrointestinal disorders | 4/10 | 0/6 | 0/3 |
| FatigueGeneral disorders | 4/10 | 2/6 | 1/3 |
| NasopharyngitisInfections and infestations | 4/10 | 1/6 | 0/3 |
| Upper respiratory tract infectionInfections and infestations | 4/10 | 1/6 | 0/3 |
| ConstipationGastrointestinal disorders | 1/10 | 0/6 | 1/3 |
| VomitingGastrointestinal disorders | 0/10 | 0/6 | 1/3 |
| Chest painGeneral disorders | 0/10 | 0/6 | 1/3 |
| Influenza like illnessGeneral disorders | 0/10 | 0/6 | 1/3 |
| SinusitisInfections and infestations | 1/10 | 0/6 | 1/3 |
Baseline Characteristics refer to the Safety Population which consisted of all participants who received at least 1 injection of zilucoplan on or after Day 1 of the extension study.
| Age, Categorical(Participants) | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 4 | 3 | 13 |
| >=65 years | 4 | 2 | 0 | 6 |
| Age, Continuous(years) | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) | Total |
|---|---|---|---|---|
| Mean | 59.6 ± 14.5 | 45.0 ± 23.0 | 35.3 ± 16.3 | 51.2 ± 19.4 |
| Sex: Female, Male(Participants) | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) | Total |
|---|---|---|---|---|
| Female | 6 | 1 | 1 | 8 |
| Male | 4 | 5 | 2 | 11 |
| Race/Ethnicity, Customized(Participants) | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) | Total |
|---|---|---|---|---|
| Black or African American | 0 | 0 | 1 | 1 |
| White | 10 | 6 | 1 | 17 |
| Not Reported | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Zilucoplan-Cohort A (Eculizumab Naïve) | Zilucoplan-Cohort B (Eculizumab Switch) | Zilucoplan (Inadequate Responder to Eculizumab) | Total |
|---|---|---|---|---|
| Not Hispanic or Latino | 10 | 5 | 3 | 18 |
| Not Reported | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Jul 2017 to primary completion in Sep 2021, 49 months.
Results were first posted in Oct 2022, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zilucoplan